RO7105979
Phase 2
RocheRO7105979 is one of 71 therapeutic programs targeting Frontotemporal Dementia. It is currently in Phase 2.
2
Indications
0
Total Trials
0
Active Trials
70
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
171 competitors in Alzheimer Disease
#DrugCompanyPhaseTrials
1Kisunla
Eli LillyPhase 3
Tirazone
SanofiPhase 3
Karxt
Bristol-Myers SquibbPhase 3
Karx-EC
Bristol-Myers SquibbPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Naproxen Sodium
BayerPhase 3
Exelon
NovartisPhase 2
Darzalex
Johnson & JohnsonPhase 2
Depo-Provera
Eli LillyPhase 2
Leukine
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for RO7105979. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company